FDA has released a social media guidance

What? The US Food and Drug Administration (FDA) has released a draft guidance document with insights on how companies should use social media channel.
Why it matters?Such is the relevance social nets have acquired for the food and drugs industry that a new regulation has been realesed.

The US Food and Drug Administration (FDA) has released a draft guidance document that offers insights into how the agency thinks companies should use—and not use—social media channels.

Background

The pharmaceutical industry's advertising and promotional materials are regulated by FDA and the Federal Trade Commission (FTC).

Information required for advertisements is extensive. Facts backed up by substantial and cited evidence , a full accounting of risks, a "fair balance" of benefits and risks of the drug, the generic name of the drug, any serious warnings ,etc. are some of the vast variety of elements they must contain.

FDA has confirmed that a full guidance document on social media—one required by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012—is on track for its anticipated July 2014 release date. Whatsmore, FDA has been working on another guidance document, focused on elements of social media.

New Social Media Guidance

The Fulfilling Regulatory Requirements for Post marketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics released on 13 January 2014 is the agency's attempt at describing how companies can submit their materials to FDA for review.

Those materials include all modern "interactive promotional media," such as blogs, micro blogs, social networking sites, online communities and live podcasts.

"Although some interactive promotional media are substantially similar in presentation and content to certain traditional promotional media, such as print media, FDA recognizes that in other cases they possess certain unique technological features and offer novel presentation and content features," the agency explains in the guidance.

Companies are now supposed to submit advertising and promotional documents to FDA through Form FDA-2253 (human) or 2301 (veterinary)  allowing FDA the opportunity to review materials instead of being forced to track them down themselves.

But as it is conceded in the guidance, "at the time of initial dissemination" isn't always practical, especially because communications are being conducted in "real time," such as on Twitter. While the guidance doesn't say anything about this, regulators appear to have come to the conclusion that real-time reports would be messy.

FDA intends to exercise its enforcement discretion using interactive promotional media that allow for real-time communications. It will also exercise its "enforcement discretion regarding the regulatory requirements for post marketing submissions related to promotional labeling and advertising," in case a firm complies with the approach recommended in the guidance.

What to Report?

According to the guidance any materials posted to a social media site under direct or indirect control or influence of the firm must submit materials to FDA's Office of Prescription Drug Promotion (OPDP), even if that influence is "limited in scope.”

In the case that a company has given a company unlimited grant money but otherwise contains no interest in posted materials, then those posted materials do not necessarily have to be submitted.

However, according to FDA: "If a firm has any control of, or influence on, the third-party site, even if limited in scope, it is responsible for submission to FDA to meet the post marketing submission requirements.” This means that the control also extends to its employees when they are acting on behalf of the company, such as a company-directed tweet from an employee's private account.

FDA recommended firms to be transparent in disclosing its involvement on a site by identifying the user-generated content (UGC) and communications of its employees or third parties acting on behalf of the firm.

When to Report?

Guidance’s first half deals with "what" needs to be submitted, while its’ second half deals with the "when" and "how" to submit material to FDA.

In the case a company is participating in active ("real-time") discussions on Twitter, it will need to submit information to FDA on a monthly basis, with a listing of all websites. Though, it won’t have to submit screenshots of conversations.

Sites controlled by third parties on behalf of the company will be subject to the same monthly reporting schedule, according to FDA.

The guidance notes also stated that FDA will need to be notified "on the first day the firm ceases to be active on a site."

 


Editorial Staff (@portada_online)

Portada is the leading source of news and analysis on the Latin Marketing and Media space. Credibility is our biggest asset: The Portada team is very passionate about producing high-quality independent content that helps drive forward the Latin Marketing and Media space.
El equipo editorial de Portada se apasiona por elaborar contenidos de alta calidad. La credibilidad es nuestro mayor activo. La misión de Portada es ayudar a profesionales de negocios y medios a comprender y alcanzar a consumidores latinoamericanos, del mercado hispano de EE UU y España.

MORE FROM PORTADA


Wall Street Firms Invest in Two Hispanic Supermarket Chains

Wall Street Firms Invest in Two Hispanic Supermarket Chains

Private-equity firms KKR and Victory Park Capital will be investing in California-based Hispanic grocery chains Mi Pueblo Food Centers and Cardenas Markets, a KKR spokeswoman announced. According to a statement both companies will continue to work independently.


Healthcare Marketing under Trump:  Karen Ignagni, President and CEO at EmblemHealth Evaluates the Situation

Healthcare Marketing under Trump: Karen Ignagni, President and CEO at EmblemHealth Evaluates the Situation

Health plan providers are among the organizations that will be most impacted by president-elect Trump's new administration. In addition, healthcare marketing under the ACA (Affordable Care Act), is to a large extent Multicultural and Hispanic marketing. Portada interviewed Karen Ignagni, President and CEO at EmblemHealth, to understand how one of the U.S. largest nonprofit health plan providers evaluates the new situation.